

Takeshita, J.; Grewal, S.; Langan, S.M.; Mehta, N.N.; Ogdie, A.; Van Voorhees, A.S.; Gelfand, J.M. (2017) [Accepted Manuscript] Psoriasis and comorbid diseases: Implications for management. Journal of the American Academy of Dermatology. ISSN 0190-9622 DOI: https://doi.org/10.1016/j.jaad.2016.07.065

Downloaded from: http://researchonline.lshtm.ac.uk/3750310/

DOI: 10.1016/j.jaad.2016.07.065

Usage Guidelines

 $Please\ refer\ to\ usage\ guidelines\ at\ http://research on line.lshtm.ac.uk/policies.html\ or\ alternatively\ contact\ research on line@lshtm.ac.uk.$

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/

Table IV: Guidelines for Age-Appropriate Cancer Screening*

Malignancy	Age	Screen	Frequency	Level of Evidence
Breast cancer ⁹⁶	50 to 74	Mammogram	Every 2 years	IA
Cervical cancer ⁹⁷	21 to 65	Pap smear	Every 3 years	IB
Colon cancer ⁹⁸	50 to 75	Fecal occult blood test (FOBT)	Yearly	
		Flexible sigmoidoscopy + FOBT	Every 5 years (flexible sigmoidoscopy) Every 3 years (FOBT)	IB
		Colonoscopy	Every 10 years	
Lung cancer ⁹⁹	55 to 80 with ≥30 pack-year history and current smoker or quit within 15 years	Low dose computed tomography of the chest	Yearly	IA

Level of evidence definitions: IA, evidence from meta-analysis of randomized controlled trials; IB, evidence from at least one randomized controlled trial; IIA, evidence from at least one controlled study without randomization; IIB, evidence from at least one other type of experimental study; III, evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; IV, evidence from expert committee reports or opinions or clinical experience of respected authorities, or both.